Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Indian American researcher developing a novel type of living T cell-based therapy to tackle obesity-induced diabetes ...
Today, the American Diabetes Association(R) (ADA) announced the awardees of the 2026 Pathway to Stop Diabetes(R) (Pathway) Award grants. The seven new awards, totaling $11.3 million in strategic ...
The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...
7d
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...
Scientists are testing whether gene editing might offer a one-time fix for high cholesterol, and approaches being developed ...
The Manila Times on MSN
Studies test whether gene-editing can fix high cholesterol
WASHINGTON, D.C. — Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might ...
In laboratory tests, the device successfully detected a molecule called miR-21, which is associated with lung cancer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results